Marks Randolph S, Graham David L, Sloan Jeff A, Hillman Shauna, Fishkoff Steven, Krook James E, Okuno Scott H, Mailliard James A, Fitch Tom R, Addo Ferdinand
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Am J Clin Oncol. 2003 Aug;26(4):336-7. doi: 10.1097/01.COC.0000020962.25210.6F.
A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.
北中部癌症治疗组对多拉司他汀15类似物LU 103793进行了一项针对晚期非小细胞肺癌（SCLC）患者的II期研究。既往未接受过治疗的患者接受该药物，剂量为2.5 mg/m²，每3周连续5天进行5分钟静脉输注。在1997年9月至1998年7月期间，该研究纳入了17例患者。共进行了42个治疗周期，毒性相对较轻。未观察到缓解情况。该药物在晚期非小细胞肺癌的治疗中似乎无活性。
